



# Introduction to Session: Meningococcal Vaccines

**Jamie Loehr, MD**  
**Chair, ACIP Meningococcal/Hib Vaccines Work Group**

June 28, 2024

# ACIP Meningococcal/Hib Vaccines Work Group

- ACIP Members on the WG
  - Jamie Loehr (Chair)
  - Wilbur Chen
  
- Ex Officio WG Members
  - Margaret Bash (FDA)
  - Matthew Clark (IHS)
  - Xin-Xing Gu (NIH)
  
- WG Liaisons and Consultants
  - Amra Resic (AAFP)
  - Mary Healy (AAP)
  - Barb Fluty (ACHA)
  - Karyn Lyons (AIM)
  - Paul Cieslak (CSTE)
  - Kathy Hsu (IDSA)
  - Pamela Doyon-Plourde (NACI)
  - Jeff Goad (NFID)
  - Jessica Cataldi (PIDS)
  - Amy Middleman (SAHM)
  - Kathy Poehling (Wake Forest)
  - Lynn Bahta (Minnesota Department of Health)
  - David Stephens (Emory)
  
- GRADE/EtR Support
  - Doug Campos-Outcalt (Arizona)
  - Rebecca Morgan (Case Western Reserve)
  
- CDC Contributors
  - Sarah Schillie (DBD/NCIRD)
  - Jennifer Collins (DBD/NCIRD)
  - Lucy McNamara (DBD/NCIRD)
  - LeAnne Fox (DBD/NCIRD)
  - Susan Hariri (DBD/NCIRD)
  - Amy Rubis (DBD/NCIRD)
  - Noele Nelson (DBD/NCIRD)
  - Alison Albert (DBD/NCIRD)
  - Shelby Miller (DBD/NCIRD)
  - Michelle Hughes (DBD/NCIRD)
  - Brian Edwards (DBD/NCIRD)
  - Isha Berry (DBD/NCIRD)
  - Madhura Vachon (DBD/NCIRD)
  - Gabrielle Cooper (DBD/NCIRD)
  - Xiaoyu Dong (ISD/NCIRD)
  - Andrew Leidner (ISD/NCIRD)
  - Ismael Ortega-Sanchez (CORVD/NCIRD)
  - Liz Velazquez (ISD/NCIRD)
  - Marc Fischer (DIDRI/NCEZID)
  - Jonathan Duffy (DHQP/NCEZID)
  - Pedro Moro (DHQP/NCEZID)
  - Tanya Myers (DHQP/NCEZID)
  - Leslie Lee (OD/NCIRD)
  - Manisha (Mo) Patel (OD/NCIRD)
  - Jessica MacNeil (ACIP Secretariat)
  - Hannah Rosenblum (ACIP Secretariat)
  - Melinda Wharton (ACIP Secretariat)

# Two Terms of Reference

- GSK's MenABCWY Vaccine
- Revisiting the adolescent meningococcal vaccine schedule

# Today's agenda

Topic	Presenter
Epidemiology Updates	Ms. Amy Rubis (CDC/NCIRD)
GSK Pentavalent Vaccine Immunogenicity and Safety	Dr. Wendy Sohn (GSK)
Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination	Dr. Sarah Schillie (CDC/NCIRD)

**All topics will be presented for information and discussion**

# Policy Questions for GSK's MenABCWY (Pentavalent) Vaccine

- Should the pentavalent vaccine be included as an option for MenACWY/MenB vaccination in people currently recommended to receive both vaccines at the same visit?
  - For example, 16 year-olds\*
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only?
  - For example, 11–12 year-olds
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenB only?
  - For example, during a serogroup B outbreak

\*16 year-olds who receive the MenB vaccine based on shared clinical decision-making

# Upcoming ACIP Meetings

- October 2024
  - GRADE/EtR
  - Cost-effectiveness analysis
  
- February 2025
  - Anticipated Vote